GSK to Acquire Nuvalent for $10.6 Billion, S&C Represents Deerfield
GSK has agreed to acquire Boston-based Nuvalent for $10.6 billion, assuming its revenue-sharing agreements. Sullivan & Cromwell advised Deerfield, Nuvalent’s largest stockholder, in this significant healthcare transaction.